ANTIDOTE

Anti-tick Vaccines to Prevent Tick-borne Diseases in Europe

Coordinatore	Academisch Medisch Centrum bij de Universiteit van Amsterdam    more  Organization address address: MEIBERGDREEF 9 city: AMSTERDAM postcode: 1105AZ contact info Titolo: Ms. Nome: Gülseren Cognome: Yalvac Email: send email Telefono: +31 20 566 6265
Nazionalità Coordinatore	Netherlands [NL]
Totale costo	3˙823˙805 €
EC contributo	2˙999˙785 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-12-01   -   2018-11-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	Academisch Medisch Centrum bij de Universiteit van Amsterdam  Organization address address: MEIBERGDREEF 9 city: AMSTERDAM postcode: 1105AZ contact info Titolo: Ms. Nome: Gülseren Cognome: Yalvac Email: send email Telefono: +31 20 566 6265	NL (AMSTERDAM)	coordinator	988˙320.00
2	"Biologicke centrum AV CR, v. v. i."  Organization address address: Branisovska 31 city: CESKE BUDEJOVICE postcode: 370 05 contact info Titolo: Ms. Nome: Zdenka Cognome: Grufikova Email: send email Telefono: +420 387 775 924 Fax: +420 385 310 338	CZ (CESKE BUDEJOVICE)	participant	565˙900.00
3	FREIE UNIVERSITAET BERLIN  Organization address address: Kaiserswertherstrasse 16-18 city: BERLIN postcode: 14195 contact info Titolo: Ms. Nome: Annegret Cognome: Körner Email: send email Telefono: 493084000000	DE (BERLIN)	participant	466˙100.00
4	ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS  Organization address address: PARQUE TECNOLOGICO EDIFICIO 801 A city: DERIO VIZCAYA postcode: 48160 contact info Titolo: Mr. Nome: Alfonso Cognome: Egaña Email: send email Telefono: +34 944 061 300 Fax: +34 944 061 301	ES (DERIO VIZCAYA)	participant	373˙400.00
5	VIROLOGICKY USTAV SLOVENSKEJ AKADEMIE VIED  Organization address address: Dubravska Cesta 9 city: BRATISLAVA postcode: 84505 contact info Titolo: Ms. Nome: Hana Cognome: Kraso?ová Email: send email Telefono: +421 259302468 Fax: +421 254774284	SK (BRATISLAVA)	participant	255˙920.00
6	GENXPRO GMBH  Organization address address: ALTENHOFTER ALLEE 3 city: FRANKFURT postcode: 60438 contact info Titolo: Ms. Nome: Cornelia Cognome: Lenhart Email: send email Telefono: +49 69 95739710 Fax: +49 6995739706	DE (FRANKFURT)	participant	208˙700.00
7	RIJKSINSTITUUT VOOR VOLKSGEZONDHEIDEN MILIEU*NATIONAL INSTITUTEFOR PUBLIC HEALTH AND THE ENVIRONMENTEN  Organization address address: Antonie Van Leeuwenhoeklaan 9 city: BILTHOVEN postcode: 3721 MA contact info Titolo: Mrs. Nome: Marjon Cognome: Hartwigsen Email: send email Telefono: +31 302742038	NL (BILTHOVEN)	participant	141˙445.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Background Ixodes ricinus transmits bacterial, protozoal and viral pathogens that cause Lyme borreliosis, babesiosis and tick-borne encephalitis respectively and exceedingly affect Central and Eastern Europe (CEE). During feeding, ticks introduce salivary proteins in the skin that interfere with host defense mechanisms. However, in animals repeated tick infestations as well as vaccination against selected tick proteins can lead to decreased pathogen transmission by inhibiting tick feeding - known as ‘tick immunity’ - or by neutralizing tick proteins that facilitate the transmission of tick-borne pathogens (TBPs). Also humans with hypersensitivity to tick-bites have a lower risk of contracting tick-borne diseases (TBDs). Therefore, anti-tick vaccines encompass an innovative strategy to prevent TBDs in humans, or animals and wildlife to indirectly reduce the risk of contracting TBDs for humans.

Overall Objective To identify and characterize tick proteins involved in ‘tick immunity’ and TBP transmission and to use this knowledge to develop anti-tick vaccines to prevent multiple human TBDs.

Methods Using state of the art proteomic and transcriptomic approaches we will identify and characterize novel tick salivary gland proteins, which will be subsequently assessed as anti-tick vaccines to protect against LB, babesiosis and TBE in animal models. In addition, through an integrated and multidisciplinary approach involving CEE public health institutes, health organizations and industrial companies we will examine how to develop anti-tick vaccines and implement these in public health systems.

Impact ANTIDotE will deliver 1) essential knowledge on the biological mechanisms involved in the pathogenesis of TBDs, 2) proof of concept of an anti-tick vaccine protecting against multiple human TBPs and 3) plans for exploitation and implementation of anti-tick vaccines, significantly contributing to downscaling the severe medical and economic burden that TBDs have on societies.'